Traws Pharma Stock Price Patterns
| TRAW Stock | 1.94 0.10 4.90% |
Momentum 67
Buy Stretched
Oversold | Overbought |
EPS Estimate Current Year (0.04) | EPS Estimate Next Year (2.30) | Wall Street Target Price 8 | Quarterly Revenue Growth 46.947 |
Using Traws Pharma hype-based prediction, you can estimate the value of Traws Pharma from the perspective of Traws Pharma response to recently generated media hype and the effects of current headlines on its competitors.
The fear of missing out, i.e., FOMO, can cause potential investors in Traws Pharma to buy its stock at a price that has no basis in reality. In that case, they are not buying Traws because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.
Traws Pharma after-hype prediction price | USD 1.88 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Check out Traws Pharma Basic Forecasting Models to cross-verify your projections. Traws Pharma After-Hype Price Density Analysis
As far as predicting the price of Traws Pharma at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Traws Pharma or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Traws Pharma, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
Traws Pharma Estimiated After-Hype Price Volatility
In the context of predicting Traws Pharma's stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Traws Pharma's historical news coverage. Traws Pharma's after-hype downside and upside margins for the prediction period are 0.09 and 12.22, respectively. We have considered Traws Pharma's daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models compare with traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Traws Pharma is dangerous at this time. Analysis and calculation of next after-hype price of Traws Pharma is based on 3 months time horizon.
Traws Pharma Stock Price Outlook Analysis
Have you ever been surprised when a price of a Company such as Traws Pharma is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Traws Pharma backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Traws Pharma, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.54 | 10.41 | 0.07 | 0.16 | 10 Events / Month | 5 Events / Month | In about 10 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | |
1.94 | 1.88 | 3.09 |
|
Traws Pharma Hype Timeline
Traws Pharma is at this time traded for 1.94. The entity has historical hype elasticity of -0.07, and average elasticity to hype of competition of -0.16. Traws is forecasted to decline in value after the next headline, with the price expected to drop to 1.88. The average volatility of media hype impact on the company price is over 100%. The price decrease on the next news is expected to be -3.09%, whereas the daily expected return is at this time at 0.54%. The volatility of related hype on Traws Pharma is about 3435.64%, with the expected price after the next announcement by competition of 1.78. About 13.0% of the company outstanding shares are owned by corporate insiders. The book value of Traws Pharma was at this time reported as 0.64. The company recorded a loss per share of 1.82. Traws Pharma had not issued any dividends in recent years. The entity had 1:25 split on the 23rd of September 2024. Given the investment horizon of 90 days the next forecasted press release will be in about 10 days. Check out Traws Pharma Basic Forecasting Models to cross-verify your projections.Traws Pharma Related Hype Analysis
Having access to credible news sources related to Traws Pharma's direct competition is more important than ever and may enhance your ability to predict Traws Pharma's future price movements. Getting to know how Traws Pharma's peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Traws Pharma may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| CING | Cingulate | (0.46) | 4 per month | 4.21 | 0.19 | 7.46 | (6.75) | 20.08 | |
| DWTX | Dogwood Therapeutics | 0.42 | 8 per month | 0.00 | (0.16) | 7.72 | (11.30) | 33.43 | |
| IMNN | Imunon Inc | (0.29) | 8 per month | 0.00 | (0.12) | 6.74 | (6.59) | 21.83 | |
| COCP | Cocrystal Pharma | 0.04 | 8 per month | 0.00 | (0.06) | 6.67 | (5.41) | 15.98 | |
| SNSE | Sensei Biotherapeutics | (2.85) | 7 per month | 5.78 | 0.01 | 17.33 | (10.69) | 36.61 | |
| BOLT | Bolt Biotherapeutics | 0.16 | 8 per month | 3.85 | 0.01 | 8.22 | (6.86) | 18.19 | |
| MBIO | Mustang Bio | (0.01) | 7 per month | 0.00 | (0.23) | 7.00 | (7.80) | 27.04 | |
| EVGN | Evogene | 0.03 | 10 per month | 0.00 | (0.05) | 4.20 | (5.22) | 21.74 | |
| BRTX | BioRestorative Therapies | (0.01) | 7 per month | 0.00 | (0.12) | 6.36 | (6.36) | 37.70 | |
| IMRN | Immuron Ltd ADR | (0.06) | 5 per month | 0.00 | (0.19) | 5.88 | (12.72) | 36.62 |
Traws Pharma Additional Predictive Modules
Most predictive techniques to examine Traws price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Traws using various technical indicators. When you analyze Traws charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
About Traws Pharma Predictive Indicators
The successful prediction of Traws Pharma stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Traws Pharma, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Traws Pharma based on analysis of Traws Pharma hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Traws Pharma's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Traws Pharma's related companies. | 2023 | 2024 | 2025 | 2026 (projected) | Current Ratio | 2.46 | 2.16 | 2.49 | 3.89 | Net Debt To EBITDA | 1.03 | 0.13 | 0.15 | 0.14 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Traws Stock Analysis
When running Traws Pharma's price analysis, check to measure Traws Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Traws Pharma is operating at the current time. Most of Traws Pharma's value examination focuses on studying past and present price action to predict the probability of Traws Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Traws Pharma's price. Additionally, you may evaluate how the addition of Traws Pharma to your portfolios can decrease your overall portfolio volatility.